Results 21 to 30 of about 10,726 (50)

Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature

European Urology Open Science, 2023
Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response.
Evangelia Vlachou, Andres Matoso, David McConkey, Yuezhou Jing, Burles Avner Johnson, 3rd, Noah M. Hahn, Jean Hoffman-Censits   +6 more
doaj  

RETRACTED: Role of miR‐490‐3p in blocking bladder cancer growth through targeting the RNA‐binding protein PCBP2

Kaohsiung Journal of Medical Sciences, 2022
MiR‐490‐3p is regarded as a tumor suppressor in many cancers, but whether miR‐490‐3p is involved in the development of bladder cancer remains unknown. BALB/c nude mice (male, 15–20 g) were used to investigate the role of MiR‐490‐3p in bladder cancer. The
Cun‐Ming Zhang, Li‐De Song, Jun‐Wei Wang, Hai‐Bo Ye, Song Chen   +4 more
doaj   +1 more source

Knockdown of CDCA8 inhibits the proliferation and enhances the apoptosis of bladder cancer cells [PDF]

PeerJ, 2020
Bladder cancer is a tumour of the urinary system with high mortality, and there is also a great lack of therapeutic targets in the clinic. Cell division cycle associated 8 (CDCA8), an important component of the vertebrate chromosomal passenger complex ...
Xin Gao, Xiaohong Wen, Haowei He, Linlin Zheng, Yibo Yang, Jinlian Yang, Haifang Liu, Xiguo Zhou, Changshun Yang, Yinyi Chen, Mei Chen, Shufang Zhang   +11 more
doaj   +2 more sources

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

OncoImmunology, 2019
Type I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma (UC) and may be an alternative treatment option for patients who do not respond to Bacillus Calmette-Guerin.
Devin Plote, Woonyoung Choi, Sharada Mokkapati, Debasish Sundi, James E Ferguson, Jon Duplisea, Nigel R. Parker, Seppo Yla-Herttuala, SUO CTC Bladder Committee, David McConkey, Kimberly S. Schluns, Colin P. Dinney   +11 more
doaj   +1 more source

Comparison and combination of mutation and methylation-based urine tests for bladder cancer detection

Biomarker Research
Background and aims Several non-invasive tests for detecting bladder cancer (BC) are commercially available and are based on detecting small panels of BC-associated mutations and/or methylation changes in urine DNA. However, it is not clear which type of
Naheema S. Gordon, Elspeth K. McGuigan, Michaela Ondasova, Jennifer Knight, Laura A. Baxter, Sascha Ott, Robert K. Hastings, Maurice P. Zeegers, Nicholas D. James, K. K. Cheng, Anshita Goel, Minghao Yu, Roland Arnold, Richard T. Bryan, Douglas G. Ward   +14 more
doaj   +1 more source

Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries

ESMO Open, 2019
The Central European Cooperative Oncology Group (CECOG) and ‘ESMO Open—Cancer Horizons’ roundtable discussion brought together stakeholders from several European Union (EU) countries involved in drug development, drug authorisation and reimbursement or ...
Nils Wilking, Anna Bucsics, Lidlija Kandolf Sekulovic, Gisela Kobelt, Andrea Laslop, Lydia Makaroff, Alexander Roediger, Christoph Zielinski   +7 more
doaj   +1 more source

Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer

Frontiers in Oncology, 2021
BackgroundBladder cancer is the 10th most common cancer and most common urothelial malignancy worldwide. Prognostic biomarkers for bladder cancer patients are required for individualized treatment. Monocarboxylate transporter 4 (MCT4), encoded by SLC16A3
Yang Zhao, Bin Zhao, Wei-Hua Yan, Yan Xia, Zhi-Hui Wang, Guo-Yang Zheng, Wen-Da Wang, Yu-Shi Zhang   +7 more
doaj   +1 more source

International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

European Urology Open Science, 2023
Background: Grade of non–muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1–3, and WHO2004 categories: papillary ...
Irene J. Beijert, Liang Cheng, Fredrik Liedberg, Karin Plass, Sean R. Williamson, Paolo Gontero, Maria J. Ribal, Marko Babjuk, Peter C. Black, Ashish M. Kamat, Ferran Algaba, David M. Berman, Arndt Hartmann, Alexandra Masson-Lecomte, Morgan Rouprêt, Antonio Lopez-Beltran, Hemamali Samaratunga, Shahrokh F. Shariat, A. Hugh Mostafid, Murali Varma, Steven Shen, Maximilian Burger, Toyonori Tsuzuki, Joan Palou, Eva M. Compérat, Richard J. Sylvester, Theo H. van der Kwast, Bas W.G. van Rhijn, Michelle R. Downes   +28 more
doaj  

Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression

Diagnostics, 2023
Bladder cancer is a common urological cancer and has the highest recurrence rate of any cancer. The aim of our study was to profile and characterize the protein expression of homeobox A13 (HOXA13) and homeobox B13 (HOXB13) genes in Malaysian bladder ...
Fee-Wai Chin, Huzlinda Hussin, De-Ming Chau, Teng-Aik Ong, Rosna Yunus, Azad Hassan Abdul Razack, Khatijah Yusoff, Soon-Choy Chan, Abhi Veerakumarasivam   +8 more
doaj   +1 more source

Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience

Frontiers in Oncology
IntroductionEnfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4.
Evangelia Vlachou, Evangelia Vlachou, Burles Avner Johnson, Burles Avner Johnson, David McConkey, David McConkey, Yuezhou Jing, Andres Matoso, Andres Matoso, Andres Matoso, Andres Matoso, Noah M. Hahn, Noah M. Hahn, Noah M. Hahn, Jean Hoffman-Censits, Jean Hoffman-Censits, Jean Hoffman-Censits   +16 more
doaj   +1 more source